# A Phase 2 Study of Vapendavir in Asthmatic Adults With Symptomatic Human Rhinovirus Infection

> **NCT02367313** · PHASE2 · COMPLETED · sponsor: **Biota Pharmaceuticals, Inc.** · enrollment: 455 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Vapendavir
- **DRUG:** Vapendavir
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02367313
- **Lead sponsor:** Biota Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 455 (ACTUAL)
- **Last updated:** 2018-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02367313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02367313, "A Phase 2 Study of Vapendavir in Asthmatic Adults With Symptomatic Human Rhinovirus Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02367313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*